Travere Therapeutics: Of Form 8k, This Current Report On Form 8k/a Is Being Filed As An Amendment To The Initial Form 8k To Provide Information Related To Mr. Cline S Compensation Arrangements In Connection With His Appointment As Chief Financial Officer, Which Had Not Yet Been Determined At The Time Of The Filing Of The Initial Form 8k. In Addition, This Current Report On Form 8k/a Updates The Effective Date Of Mr. Cline S Appointment As Chief Financial Officer To September 1, 2022, Financial Statements And Exhibits
| Show full article |
|
This functionality is available for registred users only
|
-
Full nameTravere Therapeutics Inc (formerly Retrophin Inc)
-
Registration countryUSA
-
IndustryPharmaceutical Preparation and Biotechnology
-
М/S&P/F
*** /*** /***









